Oruka Therapeutics (ORKA) Research & Development (2010 - 2024)
Oruka Therapeutics' quarterly Research & Development came in at $130000.0 in Q2 2024, down 48.82% year-on-year from $254000.0 in Q3 2023, and down 21.21% quarter-over-quarter from $165000.0 in Q1 2024.
Oruka Therapeutics has reported Research & Development for 15 years, with the latest figure at $130000.0 in Q2 2024.
- For the quarter ending Q2 2024, Research & Development fell 48.82% year-over-year to $130000.0; the trailing twelve-month figure through Jun 2024 stood at $664000.0 (down 61.6% YoY), and the FY2023 full-year result was $1.0 million, down 78.67% from the prior year.
- Research & Development for Q2 2024 stood at $130000.0, down from $165000.0 in the prior quarter.
- The five-year high for Research & Development was $3.9 million in Q4 2021, with the low at $47000.0 in Q4 2023.
- Average Research & Development over 5 years is $1.4 million, with a median of $707000.0 recorded in 2022.
- Year-over-year, Research & Development jumped 861.56% in 2021 and plunged 98.45% in 2022.
- Tracing ORKA's Research & Development over 5 years: stood at $3.2 million in 2020, then climbed by 23.0% to $3.9 million in 2021, then sank by 98.45% to $61000.0 in 2022, then retreated by 22.95% to $47000.0 in 2023, then soared by 176.6% to $130000.0 in 2024.
- The last three Research & Development figures came in at $130000.0 (Q2 2024), $165000.0 (Q1 2024), and $47000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 165,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | 322,000.00 |
| Jun 30, 2023 | 254,000.00 |
| Mar 31, 2023 | 390,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 1.49 Mn |
| Mar 31, 2022 | 2.18 Mn |
| Dec 31, 2021 | 3.94 Mn |
| Sep 30, 2021 | 3.44 Mn |
| Jun 30, 2021 | 3.58 Mn |
| Mar 31, 2021 | 2.88 Mn |
| Dec 31, 2020 | 3.20 Mn |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 372,000.00 |
| Mar 31, 2020 | 365,000.00 |
| Dec 31, 2019 | 384,000.00 |
| Sep 30, 2019 | 347,000.00 |
| Jun 30, 2019 | 440,000.00 |
| Mar 31, 2019 | 662,000.00 |
| Dec 31, 2018 | 625,000.00 |
| Sep 30, 2018 | 740,000.00 |
| Jun 30, 2018 | 1.15 Mn |
| Mar 31, 2018 | 1.72 Mn |
| Dec 31, 2017 | 2.83 Mn |
| Sep 30, 2017 | 3.49 Mn |
| Jun 30, 2017 | 4.51 Mn |
| Mar 31, 2017 | 3.25 Mn |
| Dec 31, 2016 | 3.12 Mn |
| Sep 30, 2016 | 3.72 Mn |
| Jun 30, 2016 | 2.91 Mn |
| Mar 31, 2016 | 2.59 Mn |
| Dec 31, 2015 | 1.89 Mn |
| Sep 30, 2015 | 1.72 Mn |
| Jun 30, 2015 | 1.75 Mn |
| Mar 31, 2015 | 1.71 Mn |
| Dec 31, 2014 | 1.58 Mn |
| Sep 30, 2014 | 1.34 Mn |
| Jun 30, 2014 | 1.40 Mn |
| Mar 31, 2014 | 1.31 Mn |
| Dec 31, 2013 | 1.79 Mn |
| Sep 30, 2013 | 714,000.00 |
| Jun 30, 2013 | 246,000.00 |
| Mar 31, 2013 | 181,000.00 |
| Dec 31, 2012 | 191,000.00 |
| Sep 30, 2012 | 156,000.00 |
| Jun 30, 2012 | 322,000.00 |
| Mar 31, 2012 | 422,000.00 |
| Dec 31, 2011 | 595,000.00 |
| Sep 30, 2011 | 533,000.00 |
| Jun 30, 2011 | 497,000.00 |
| Mar 31, 2011 | 690,000.00 |
| Dec 31, 2010 | 860,000.00 |
| Sep 30, 2010 | 726,000.00 |
| Jun 30, 2010 | 700,000.00 |